Stock CYTRX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. CytRx Corporation Nasdaq

Equities

US2328283013

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for CytRx Corporation
Mar. 27 LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 11 Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol DJ

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LADX Stock
  4. Stock
  5. News CytRx Corporation
  6. Analyst Reco.